Ryder, R., Holman, R., & Gwilt, M. (2016). This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes. Association of British Clinical Diabetologists.
शिकागो शैली (17वां संस्करण) प्रशस्ति पत्रRyder, R., R. Holman, और M. Gwilt. This House Believes That Sulphonylureas Should Not Be Used Routinely as Second-line Treatments for Patients with Type 2 Diabetes. Association of British Clinical Diabetologists, 2016.
एमएलए (9वां संस्करण) प्रशस्ति पत्रRyder, R., et al. This House Believes That Sulphonylureas Should Not Be Used Routinely as Second-line Treatments for Patients with Type 2 Diabetes. Association of British Clinical Diabetologists, 2016.
चेतावनी: ये उद्धरण हमेशा 100% सटीक नहीं हो सकते हैं.